Advertisement

Medicare Part D data show big spending on brand names

By Bob Herman  |  May 02, 2015

Medicare shelled out more than $103 billion on prescription drugs in 2013, raising questions about why the government pays so much for brand-name pharmaceuticals and how physicians prescribe drugs for their patients.

Panel recommends labeling change for AstraZeneca's diabetes drug Onglyza

By Steven Ross Johnson  |  April 14, 2015

An advisory panel to the U.S. Food and Drug Administration voted Tuesday to recommend the agency require drugmaker AstraZeneca to change the labeling of its diabetes medication Onglyza to add safety information to reflect a heightened risk for heart failure associated with its use.

China fines GlaxoSmithKline $492M for bribery

By Associated Press  |  September 19, 2014

Drugmaker GlaxoSmithKline was fined $492 million on Friday for bribing doctors in China, the biggest such penalty ever imposed by a Chinese court.

Pfizer's 2Q profit sinks 79% but tops forecasts

By Associated Press  |  July 29, 2014

Pfizer's second-quarter earnings plunged 79% from last year, when the world's second-largest drugmaker booked a $10 billion-plus gain from a business spinoff.

Merck 2Q profit more than doubles

By Associated Press  |  July 29, 2014

A big one-time gain and a tax benefit helped drugmaker Merck & Co. more than double its second-quarter profit, improve its profit forecast and top analysts' expectations.

Antiviral-drug maker fights pediatricians' new advice

By Associated Press  |  July 28, 2014

A costly drug given mostly to premature babies is at the center of a clash between the manufacturer and the nation's leading pediatrician's group, which recommends scaling back use of the medicine.

Tax reform fears driving Big Pharma mergers

Tax reform fears driving Big Pharma mergers

By Beth Kutscher  |  July 19, 2014

The rumblings that corporate tax reform will close favorable loopholes for pharmaceutical and biotechnology companies are getting louder, fueling a rush of high-dollar cross-border deals.

Drug prices spotlighted in AstraZeneca deal

By Beth Kutscher  |  May 24, 2014

With a May 26 deadline looming, British drug giant AstraZeneca is holding firm in its refusal to accept a $119 billion offer from Pfizer to create the world's largest pharmaceutical company.

Advertisement
Modern Healthcare Daily

Award winning coverage of healthcare business and policy news.

The Modern Healthcare app includes a personalized home screen, strong search functionality and immediate downloads from the industry's leading healthcare media brand.